The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Real-world efficacy and safety of belantamab mafodotin in patients with triple class-exposed myeloma
Ioannis Ntanasis-Stathopoulos, MD, National and Kapodistrian University of Athens, Athens, Greece, shares the results of a real-world analysis of belantamab mafodotin in patients with triple class-exposed (TCE) multiple myeloma. Dr Ntanasis-Stathopoulos explains that the data was comparable to that of the DREAMM-2 study (NCT03525678) and demonstrated that belantamab mafodotin is a feasible and effective option for patients with TCE myeloma. Dr Ntanasis-Stathopoulos explains that belantamab mafodotin is an easily accessible off-the-shelf treatment option that could play a role in combination therapies and in earlier lines of treatment. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
